Hydroxychloroquine-induced myopathy

Journal of Clinical Rheumatology

Volumn 16, Issue 1, 2010, Pages 28-31

  Kwon, Jun Beom ^a   Kleiner, Anatole ^b   Ishida, Koto ^c   Godown, Justin ^c   Ciafaloni, Emma ^d   Looney, R John ^b  

^a Department of Medicine ^*  (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cardiotoxicity; Hydroxychloroquine; Myopathy; Neuromyotoxicity

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITRATE CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYCHLOROQUINE SULFATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOOP DIURETIC AGENT; METOPROLOL SUCCINATE; MULTIVITAMIN;

AGED; ARTICLE; CARDIOTOXICITY; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; COUGHING; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; MUSCLE BIOPSY; MYOPATHY; PRIORITY JOURNAL; SYMPTOM; THORAX PAIN;

AGED; ANTIRHEUMATIC AGENTS; APNEA; FEMALE; HEART FAILURE; HUMANS; HYDROXYCHLOROQUINE; MUSCULAR DISEASES;

EID: 77950364943     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181c47ec8     Document Type: Article

References (14)

1. Richards AJ. Hydroxychloroquine myopathy. J Rheumatol. 1998;25:1642-1643.
2. Dereure O. Drug induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2:253-262.
3. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheu-matol. 2000;27:2927-2931.
4. Hendrix JD, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol. 1992;31:458-466.
5. Nord JE, Shah PK, Rinaldi RZ, et al. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of literature. Semin Arthritis Rheum. 2004;33:336-351.
6. Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with, hydroxychloroquine for connective tissue diseases. Rheumatology. 2007;46:808-810.
7. Bolanos-Meade J, Zhou L, Hoke A, et al. Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease. Am J Hematol. 2005;78:306-309.
8. Casado E, Gratacós J, Tolosa C, et al. Antimalarial myopathy: an underdi-agnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65:385-390.
9. Keating RJ, Bhatia R, Amin S, et al. Hydroxychloroquine-induced cardio-toxicity in a 39-year-old with systemic lupus erythematosus and systolic dysfunction. J Am Soc Echocardiogr. 2005;18:891.c1-c5.
10. Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology. 2007;107: 73-80.
11. Siddiqui AK, Huberfeld SI, Weidenheim KM, et al. Hydroxychloroquine- induced toxic myopathy causing respiratory failure. Chest. 2007;131:588-590.
12. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatc drug. Semin Arthritis Rheum. 1993;23:82-91.
13. Millard TP, Kirk A, Ratnavel R. Cutaneous hyperpigmentation during therapy with hydroxychloroquine. Clin Expl Dermatol. 2004;29: 92-93.
14. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on toll-like receptors? Arthritis Rheum. 2006;54:3068-3070.